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Available epidemiological data shows that an average number of 
59 cases of tetanus per year are still reported in Italy. Most of 
cases (80.2%) occur in subjects > 64 years-old. Furthermore, the 
proportion of females among subjects ≥ 65 years-old is signifi-
cantly higher than males (87.7% vs. 64.4%, p < 0.0001).
Seroprevalence data show that the percentage of subjects with 
protective tetanus antibody levels (> 0.1  IU/ml) decreases with 
increasing age. Most people aged ≥ 65 years are unprotected. The 
antibody levels are higher in males than females (p < 0.001) in 
subjects > 25 years-old.
Conversely, extensive childhood immunization and adequate 
boosting vaccination of adults led to the near-elimination of diph-
theria in Western countries.
The current Italian National Immunization Prevention Plan 2012-
2014 recommends the administration of a primary vaccine course 
in the first year of life and booster at the preschool age, in ado-
lescents and in adults every 10 years. Nevertheless, the need for 
decennial booster doses is debated by some experts, who state 
that the best time to offer a single dose of vaccine against tetanus 
and diphtheria is the age of 50, since low levels of antibody titers 
are observed.
Considering the availability of combined vaccines against diph-
theria, tetanus and pertussis (DTaP or dTaP), and the increasing 
incidence of pertussis in infants, who are at highest risk of serious 
complications, in adolescents and in adults, some countries have 
introduced decennial dTaP in the adults immunization schedule. 
It is desirable that this recommendation is also introduced in the 
future Italian Immunization Prevention Plan.
The present review overviews the epidemiological data and the 
immunization strategies against tetanus, diphtheria and pertussis 
in Italy, discussing the rationale not only of decennial dT booster 
but also of the dTaP booster.
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Summary
Introduction
Tetanus and diphtheria are two serious infectious diseas-
es caused by powerful exotoxins produced by Clostridi-
um tetani and Corynebacterium diphtheriae respective-
ly, with often-fatal outcome.
C.  tetani is an anaerobic gram-positive bacteria, that 
may develop a terminal spore. The spores are widely 
distributed in soil, in the inanimate environment and in 
animal intestinal tract and feces. Tetanus occurs by pen-
etration of spores through contaminated wounds, lacera-
tions and abrasions. Deep wounds, with lacerated and 
bruised margins, devitalized tissue, contaminated with 
soil, are at high risk of tetanus. Toxins disseminate via 
blood and lymphatics and interfere with release of neu-
rotransmitters [1]. Tetanus is infectious, but not conta-
gious and natural infection does not confer lifelong im-
munity. Unlike person-to-person transmissible diseases, 
high vaccination coverage (VC) in the pediatric age does 
not provide herd immunity. Furthermore, it is almost im-
possible to eliminate the disease because of the wide-
spread presence of tetanus spores in the environment. 
Consequently, inadequately immunized subjects are po-
tentially at risk [2].
Clinically, it is characterized by generalized rigidity and 
convulsive spasms of skeletal muscle and by autonomic 
nervous system disfunctions, after an average incubation 
period of 7 days [3].
C.  diphtheriae is a gram-positive, uncapsulated bacil-
lus, most often transmitted via the aerosol route. Human 
asymptomatic carriers are a major source of infection. 
Whereas toxigenic strains of C.  diphtheriae most fre-
quently cause pharyngeal diphtheria, systemic toxicity, 
myocarditis and polyneuropathy, non-toxigenic strains 
usually cause cutaneous disease. The average incubation 
period of respiratory diphtheria is 2-5 days. Distinctive 
pathologic findings of severe respiratory diphtheria in-
clude mucosal ulcers with a pseudomembranous coat-
ing, which may extent from the pharynx into bronchial 
airways and may result in fatal airway obstruction. Cuta-
neous diphtheria is commonly a secondary infection that 
follows a primary skin lesion due to trauma, allergy or 
autoimmunity [4, 5].
The present review overviews the epidemiological 
data and the immunization strategies against tetanus, 
diphtheria and pertussis in Italy, discussing the ration-
ale not only of decennial dT booster but also of the 
dTaP booster.
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Epidemiology of tetanus and diphtheria 
in Italy
Tetanus
From the second half of 1950s to the mid of 1960s 722 
cases of tetanus (1.4 cases per 100,000 population) were 
notified yearly in Italy. Up to the half of 1970s the num-
ber of cases considerably decreased, as a consequence 
of the introduction of universal childhood immunization 
during 1960s. Subsequently, the decrease of the cases 
occurred more slowly, reaching the all-time low of 65 
cases in 1991. From 1992 to 2000 the number of cases 
remained stable, with a mean of 102 cases per year (0.2 
cases per 100,000 population). The last case of neo-
natal tetanus dates back to 1982. The reduction in the 
incidence observed between the 1970s and 1990s was 
evident in all age groups. During the considered period, 
the highest incidence rate was observed in subjects ≥ 65 
years-old. The greatest reduction (20-fold) in incidence 
occurred in the 15-24 years age group. Conversely, the 
incidence in the elderly decreased only by a half. Fur-
thermore, the percentage of cases ≥ 65 years of age in-
creased from 40% in the 1970s to 70% in the 1990s. 
These observations have been confirmed by the analy-
sis of the median age of cases, which increased from 58 
years in the 1970s to 63 years in the 1980s and 71 years 
in the 1990s. Analyzing epidemiological data by gender, 
in the 1990s, rates were higher in woman than in male 
among subjects ≥ 65 years. This is probably due to the 
fact that in this age group male counterparts were vacci-
nated as military recruits or because of job-related risks. 
As incidence rate, the case-fatality also decreased from 
64% in the 1970s to 40% in the 1990s [2].
Available data about the decade 2001-2010 shows that 
an average number of 59 cases (range: 46-71) per year 
(1 per 1,000,000 population) are still reported in Italy. 
Despite high VC were achieved, Italy accounts for 
most cases reported in the European Union (EU)  [6] 
and tetanus incidence in Italy is about 10 times higher 
than the average incidence reported in the USA and 
Australia  [7, 8]. As observed in previous years and in 
other developed countries [9], most of cases (80.2%) oc-
cur in subjects >  64 years-old, with an incidence rate 
equal to 4.1 per 1,000,000 population. The estimated 
incidence in Italy in the decade 2001-2010 in female 
is 5.2 per 1,000,000 population (68% of cases), that is 
over three-fold higher than in male (1.4 per 1,000,000 
population). The estimated incidence in Italy in the dec-
ade 2001-2010 in female is 5.2 per 1,000,000 popula-
tion (68% of cases), that is over three-fold higher than 
in male (1.4 per 1,000,000 population). Furthermore, 
the proportion of female among subjects ≥ 65 years-old 
was significantly higher than males (87.7% vs. 64.4%, 
p < 0.0001). The average annual hospitalization rate of 
1.6 per 1,000,000 population, with a median length of 
stay of 25 days. 79.8% of patients was > 64 years-old 
and 69% involved female. The estimated case fatality 
ratio was 16.5%. National mortality data were available 
for the years 2001-2003 and 2006-2010. 169 deaths were 
reported, with a mean annual number of 21 (range: 17-
27). Seroprevalence data about the same period are also 
available and show that the percentage of subjects with 
protective tetanus antibody levels (> 0.1 IU/ml) decreas-
es with increasing age from 87% (95% CI: 84.1-89.5) in 
the age group 15-24 years to 43.4% (95% CI: 38.6-48.3), 
26.6% (95% CI: 21.4-32.2), 27.9% (95% CI: 22.3-33.9) 
and 17.1% (95% CI: 6.6-33.6) in the age groups 45-64, 
65-74, 75-84 and ≥  85 years, respectively. Therefore, 
most people aged ≥  65 years are unprotected and this 
is probably due to inadequate VC. Furthermore, most 
elderly people probably never received a primary vac-
cination course. Low antibody levels observed in young 
adults suggest poor compliance with booster recommen-
dations. The observed antibody levels were higher in 
males than females (p < 0.001) from age 25 years. This 
is probably due to the fact that males had more oppor-
tunities for being vaccinated compared to female, such 
as compulsory military service or work. Then, despite 
the availability of safe and effective vaccines, too many 
cases and deaths still occur, especially among older 
adults [10].
Diphtheria
Before the introduction of universal vaccination with 
aluminum-containing toxoids in 1939 in Italy, the dis-
ease was a widespread disease and major cause of death, 
especially in children. The number of reported cases per 
year and deaths until 1940 were 20-30,000 and 1,500, 
respectively. In the 1950s and 1960s, the number of re-
ported cases reached several thousands per year. Then, 
between 1973 and 1982 the number of cases fell to a few 
per year. Since then the disease has become exception-
al: only 5 cases of diphtheria were registered between 
1990 and 1998, one of which was imported. From 1999 
to 2006 no case has been reported. Extensive childhood 
immunization and adequate boosting vaccination of 
adults led to the near-elimination of diphtheria in West-
ern countries [11, 12]. Data obtained from a seropreva-
lence study conducted in eight Italian cities from June 
1993 to June 1995, demonstrated the progressive reduc-
tion in antibody titers as age increases. The percentage 
of subjects with unprotective antitoxin concentrations 
progressively increased from 7.2% in the 1-10 years age 
group to 33.4% in subjects aged > 60 years. This is re-
lated to the fact that, at that time, no further booster was 
recommended after the childhood immunization course 
and it suggests that the immunological memory declines 
with age [13].
Prevention of tetanus and diphtheria
a) The available vaccines
In the 1920s, Ramon at the Institut Pasteur developed 
a method for inactivating tetanus and diphtheria toxins, 
which led to the development of tetanus and diphtheria tox-
oids, which were nontoxic but highly immunogenic [1, 5].
Tetanus and diphtheria toxoids are produced from the 
cell-free purified toxins extracted from the strain of 
C. diphtheriae and from C. tetani. They are treated with 
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formaldehyde to convert toxin into toxoid and it is then 
adsorbed onto an aluminum salt to improve its immuno-
genicity [1, 5, 14].
Tetanus toxoid is available as a single-antigen prepa-
ration, combined with diphtheria toxoid as pediatric 
diphtheria-tetanus toxoid (DT) or reduced tetanus-diph-
theria (Td) formulated for adolescents and adults, and 
with both diphtheria toxoid and acellular pertussis vac-
cine as DTaP or Tdap. DTaP replaced DTP (diphtheria 
and tetanus toxoids and whole-cell pertussis vaccine) in 
1997 [3]. Tetanus toxoid is also available as combined 
products diphtheria/tetanus/acellular pertussis/inacti-
vated polio vaccine (DTaP-IPV), diphtheria/tetanus/
acellular pertussis/hepatitis B/inactivated polio vaccine 
(DTaP-HepB-IPV) and diphtheria/tetanus/acellular per-
tussis/inactivated polio vaccine/Haemophilus influenzae 
type b (DTaP-IPV-Hib) [1, 5, 14].
Seroprotection rate evaluated up to 10 years after booster 
vaccination of children at pre-school age demonstrated 
that almost all subjects achieve antitoxin levels against 
both diphtheria and tetanus considerably greater than 
the protective level of 0.1 IU/ml. Nevertheless, antitoxin 
levels decrease with time in adulthood [15].
b) Strategies for preventing diphtheria, 
tetanus (and whooping cough) in Italy
Tetanus toxoid vaccine was introduced in 1938 as com-
pulsory vaccine only for military personnel. In 1963 it 
became compulsory also for children two-year-old and 
for specific work categories and in 1968 the vaccine is 
administered during the first year of life [10].
Immunization with diphtheria toxoid is available from 
1929 and it has been compulsory for all newborns since 
1939. Since 1969, diphtheria vaccine is administered 
combined with tetanus toxoid. Furthermore all newborn 
receive a primary course that includes three doses since 
1981 [13].
The current Italian National Immunization Prevention 
Plan 2012-2014 recommends the administration of the 
vaccine against tetanus and diphtheria (in association 
with the vaccine against polio, whooping cough, hepatitis 
B and Haemophilus influenzae type b) in the first year of 
life (3 doses) [16]. In the preschool age a booster of diph-
theria, tetanus, pertussis and polio (DTP-IPV) is recom-
mended and a second booster with the adult formulation 
(dTpa) is timetabled in adolescent age (11-18 years). In 
adults dT booster doses are recommended every 10 years, 
even if it is recommended that if the adult has never been 
vaccinated for DT one of three doses of vaccine should 
also contain antigens for pertussis. It is recommended that 
adults with unknown dT immunization history begin or 
complete the primary course. The adult primary course 
included two doses of dT and a third dose with dTap vac-
cine. The following booster should be administered every 
10 years after the primary course and at least one of the 
booster doses should be replaced by a dTap dose.
Booster recommendations vary among countries, tak-
ing into account the seroepidemiological data of teta-
nus and diphtheria and the incidence in different age 
groups [9, 17-20]. Nevertheless, the need for decennial 
booster doses is debated by some experts [21-25]. Some 
authors stated that the interval between adult boosters 
could be wider, maybe of 20 years  [25]. Furthermore, 
according to some experts, the best time to verify tetanus 
immunization status and to offer a single Td dose is the 
age of 50 [26]. This strategy could be appropriate even 
in Italy, considering that the lowest level of antibody ti-
ters was found in adults ≥ 45 years of age [10]. Surely, 
strategies to improve vaccine uptake in this age group 
should be implemented.
Post-exposure prophylaxis for tetanus
Appropriate wound management in the Emergency De-
partments is also essential for preventing tetanus [27].
Wound management requires the consideration of the 
need for (i) passive immunization with tetanus immune 
globulins (TIG); and (ii) active immunization with vac-
cine (Tdap or Td). The TIG affords temporary immu-
nity by directly providing antitoxin. This ensures the 
achievement of protective levels of antitoxin even if 
an immune response has not yet occurred [1]. The type 
of treatment depends on the tetanus risk assessment of 
wounds and the patient’s immunization history (Tab. I).
Rationale for DTaP booster
The immunological pressure exerted by high VC against 
pertussis achieved in the pediatric age and the relatively 
short duration of induced immunity against the disease, 
have allowed a reduction not only in the pertussis inci-
dence in children, but also the chances of natural boosting 
and the subsequent increasing number of cases among 
adolescents or adults who have lost their immunologi-
cal protection and in infants that have not yet begun or 
completed their primary immunization course [28-31].
For these reasons, most countries that have included vac-
cination against pertussis in their national immunization 
schedule, recommend a booster dose at preschool age 
and a second booster in adolescents, after the primary 
Tab. I. preventive strategies of postexposure tetanus.
Immunization history 
(number of doses) for tetanus
Tetanus risk assessment of wounds
Low-risk wounds High-risk wound
dT-DTP-dTp1 TIG2 dT-DTP-dTp1 TIG2
Unknown or < 3 doses yes No yes yes
≥ 3 doses No3 No No4 No
1 Administration of combined vaccine against diphtheria and tetanus (dT) or against diphtheria, tetanus and pertussis (dTp or dTp); 2 administration of 
anti-tetanus immunoglobulin; 3 yes, if ≥ 10 years have elapsed since the last tetanus toxoid-containing vaccine dose; 4 yes, if ≥ 5 years have elapsed since 
the last tetanus toxoid-containing vaccine dose.
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course of DTaP in the first year of life. Furthermore, in 
some countries a decennial booster in adults is recom-
mended, in consideration of the relative limited duration 
of immunity induced both by natural infection and vac-
cination [32, 33].
In Italy in accordance to the “Lifetime Vaccination Cal-
endar” proposed by a coalition of scientific societies and 
professional organizations, such as the Italian Society of 
Hygiene, Preventive Medicine and Public Health (SItI), 
the Italian Federation of Paediatricians (FIMP), the Ital-
ian Society of Pediatrics (SIP) and the Italian Society 
of General Practitioners (SIMMG), a decennial dTap 
booster is recommended in adults (e.g., childcare work-
ers, healthcare workers, teachers, etc.) [34].
Furthermore, the current Italian National Immunization 
Prevention Plan 2012-2014 recommends that the adults 
who have never been vaccinated for DT receive one dose 
of dTap among the three doses of the primary course [16].
Prevention of pertussis in infants  
(the “Cocoon” strategy)
Available epidemiological data show that the burden of 
pertussis in terms of incidence mainly involves infants, 
adolescents and adults. Infants suffer from the most se-
rious complications of the disease, including death. A 
decreased risk of infection in newborns can be achieved 
with the immunization of parents, family members and 
cohabitants who have a close contact with newborns, 
who are unvaccinated or incompletely immunized. The 
booster dose should be administered preferably in the 
months preceding the birth or immediately after the de-
livery. The vaccination of pregnant women during the 
third trimester or late second trimester is recommended 
also by the ACIP, in conjunction with the American Col-
lege of Obstetrics and Gynecology and is included in the 
vaccination schedules of some Western countries, e.g. 
Netherlands and United Kingdom [32, 33, 35, 36].
This strategy might be combined with a booster target-
ing adults at high risk of transmitting B.  pertussis in-
fection to vulnerable infants (e.g., childcare workers, 
healthcare workers, teachers, etc.), as recommended in 
the current Italian National Immunization Prevention 
Plan 2012-2014 [16].
Objectives of vaccine strategies against diphtheria-
tetanus-pertussis implemented in Italy
The implemented strategies should achieve the follow-
ing objectives [16]:
•	 achievement and maintaining VC with three doses of 
DTaP administered at 24 months of age and with the 
booster dose at the pre-school age ≥ 95%;
•	 achievement and maintaining of VC with the “boost-
er” dose of DTaP administered in adolescents ≥ 90%.
Conclusions
The question “are dT boosters really necessary every 
10 years?” should be rephrased as follows: “are dTaP 
boosters really necessary every 10 years?”
The answer is “yes, certainly”, especially taking into ac-
count the estimated duration of immunity against per-
tussis (no more than 10 years) and the need to maintain 
high protective vaccine-induced antibody titers. Fur-
thermore, the decennial booster involves the advantage 
of maintaining high protection even against tetanus and 
diphtheria, thanks to the availability of safe and effective 
combined vaccines.
It is desirable that this recommendation will also intro-
duced in the future National Immunization Prevention 
Plan.
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